Lorelei Ann Mucci
Professor

Lorelei Ann Mucci

Professor of Epidemiology

Epidemiology

lmucci@hsph.harvard.edu


Overview

My major area of research and teaching is cancer epidemiology. I am the Director of the Cancer Epidemiology and Cancer Prevention Program (Area of Interest) within the Department of Epidemiology here at the Harvard T.H. Chan School of Public Health (HSPH). In addition, I am Leader of the Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center.

After receiving my doctoral degree in epidemiology at the Harvard T.H. Chan School of Public Health (formerly the Harvard School of Public Health), I trained as a post-doctoral fellow in cancer epidemiology at the Karolinska Institutet, Sweden. At the Karolinska, I gained expertise in using nationwide health registries to examine cancer etiology and formed a long-term partnership with epidemiology colleagues in the Nordic countries. For the past 9 years, my primary faculty appointment has been at the Harvard Chan School, where my research uses integrative molecular epidemiology approaches within cohorts in the United States and globally to investigate research questions focused on cancer etiology, mortality, and survivorship. I serve as co-Principal Investigator for the Health Professionals Follow-up Study (https://sites.sph.harvard.edu/hpfs/) as well as IRONMAN (see below). Below is a summary of some major areas of interest.


Bibliography

Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21).

Hayes B, Brady L, Sheill G, Baird AM, Guinan E, Stanfill B, Dunne J, Holden D, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, Mucci LA, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell DM, Sheils O, O'Leary JJ, Rudman S, McDermott R, Finn S.

Cancers (Basel). 2021 Sep 18. 13(18). PMID: 34572916

Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).

Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M.

Cancer Genet. 2021 Aug 28. 258-259:61-68. PMID: 34551377

Dairy consumption, plasma metabolites, and risk of type 2 diabetes.

Drouin-Chartier JP, Hernández-Alonso P, Guasch-Ferré M, Ruiz-Canela M, Li J, Wittenbecher C, Razquin C, Toledo E, Dennis C, Corella D, Estruch R, Fitó M, Eliassen AH, Tobias DK, Ascherio A, Mucci LA, Rexrode KM, Karlson EW, Costenbader KH, Fuchs CS, Liang L, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB.

Am J Clin Nutr. 2021 07 01. 114(1):163-174. PMID: 33742198


News

Diet may influence risk of aggressive prostate cancer

Dietary patterns that are associated with inflammation and insulinemia—a condition marked by high levels of insulin in the blood—may put men at an increased risk for aggressive forms of prostate cancer, according to new research led by Harvard…

Research Dream Team to focus on multiple myeloma precursors

Lorelei Mucci, associate professor of epidemiology at Harvard T.H. Chan School of Public Health, is among the researchers participating in a new Stand Up To Cancer (SU2C) Dream Team focused on revolutionizing the treatment of multiple myeloma. Stand…